Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces its participation in two major events in the US : 2015 BIO International Convention (Biotechnology Industry Organization), June 15-18 in Philadelphia, and French Life Sciences Days, June 17-18, 2015, in New York.
BIO International Convention is the largest, most influential biotechnology meeting in the world. The 2015 edition will feature 1,700 exhibitors and include more than 60 national and regional pavilions that will host many companies from these regions. At this event, Quantum Genomics will continue its discussions with several of the leading global pharmaceutical companies.
Organized by France Biotech, the second edition of the French Life Sciences Days aims to strengthen the links between listed French Life Sciences companies and major international investors. Quantum Genomics will meet again with US investors in continuation of the 2014 edition.
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.
Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).
Chairman & Chief Executive Officer
+33 1 85 34 77 77
CFO – Investor Relations
+33 1 85 34 77 75
|ACTUS finance & communication
+33 1 53 67 36 73
Powered by Actusnews Wire (press release services) ©